Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 7/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.33 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | KDM5A | P29375 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.32 |
| ▸ | SSTR4 | P31391 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14652106 | 0.87 | MME (0.41) | MMEL3MBTL1SMYD3CSNK2A2CSNK2A1 | |
| SCHEMBL14654962 | 0.82 | L3MBTL1 (0.37) | MMEL3MBTL1SMYD3EPHX1LMNA | |
| SCHEMBL14654977 | 0.81 | L3MBTL1 (0.38) | MMEL3MBTL1SMYD3EPHX1LMNA | |
| SCHEMBL14654900 | 0.80 | EPHX1 (0.37) | MMEL3MBTL1SMYD3EPHX1LMNA | |
| SCHEMBL15906227 | 0.79 | EPHX1 (0.44) | MMEEPHX1CSNK2A2CSNK2A1SSTR4 | |
| SCHEMBL18431346 | 0.70 | L3MBTL1 (0.39) | L3MBTL1SMYD3EPHX1EPHX2 | |
| SCHEMBL22388662 | 0.70 | TEAD1 (0.40) | L3MBTL1SMYD3EPHX1EPHX2 | |
| SCHEMBL18431408 | 0.70 | TEAD1 (0.40) | L3MBTL1SMYD3EPHX1EPHX2 | |
| SCHEMBL2454699 | 0.69 | SMYD3 (0.40) | L3MBTL1SMYD3EPHX1EPHX2 | |
| SCHEMBL2456036 | 0.69 | SMYD3 (0.44) | SMYD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130023514-A1 | SUBSTITUTED PYRROLOTRIAZINES AS PROTEIN KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023514-A1 | SUBSTITUTED PYRROLOTRIAZINES AS PROTEIN KINASE INHIBITORS | STK25, MAP3K15, MAP3K5 | MME 4725/4885L3MBTL1 4518/4885SMYD3 3232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.